Relmada Therapeutics, Inc. Stock Analysis & AI Score
Relmada Therapeutics, Inc. (RLMD) has an ST Score of 63.7 (B), driven by its Financial Strength (A+) and held back by its Momentum (C). Analysts rate it Buy with a $12.00 price target (+278.5% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Relmada Therapeutics, Inc. (RLMD) has an ST Score of 63.7 (B), driven by its Financial Strength (A+) and held back by its Momentum (C). Analysts rate it Buy with a $12.00 price target (+278.5% upside).
- Strongest
- Financial StrengthA+
- Weakest
- MomentumC
All factor grades
- Financial StrengthA+
- ValuationA
- ForecastA
- ProfitabilityB
- GrowthB
- MomentumC
- Piotroski2/9
Contact
RLMD stock: frequently asked questions
What is RLMD's ST Score?
Relmada Therapeutics, Inc. (RLMD) has an ST Score of 63.7 (B), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is RLMD a buy, hold, or sell?
Analysts rate RLMD a Buy, with a price target of $12.00 (+278.5% vs the current price). Our ST Score grades it B (63.7/100). The ST Score is a data-driven signal, not a recommendation.
What are RLMD's factor grades?
Valuation A, Profitability B, Financial Strength A+, Momentum C, Growth B, Forecast A.
What is RLMD's valuation grade?
Relmada Therapeutics, Inc. (RLMD) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is RLMD's growth grade?
Relmada Therapeutics, Inc. (RLMD) earns a growth grade of B, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is RLMD's profitability grade?
Relmada Therapeutics, Inc. (RLMD) earns a profitability grade of B, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is RLMD's financial strength grade?
Relmada Therapeutics, Inc. (RLMD) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for RLMD?
The average analyst price target for Relmada Therapeutics, Inc. (RLMD) is $12.00 from 8 analysts, which is +278.5% versus the recent price of $3.17.
What is RLMD's Piotroski score?
Relmada Therapeutics, Inc. (RLMD) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.